Image Credit: Yahoo Finance
Recode Therapeutics, a leading clinical-stage genetics medicines company utilizing tissue-specific delivery to strengthen the next generation of gene correction and mRNA therapeutics, has closed above $29 million in additional financing. The company confirmed the extended contribution from the Cystic Fibrosis Foundation (CF Foundation) and a new research partnership with Praxis Precision Medicines, Inc. Finance and investment play a major role in drug discovery and development. Recode’s efforts to strengthen the portfolio will surely bring a strong impact in the precision medicines area and accelerate effective treatment. This is an indirect profit for the long run.
The MD, MBA, M. Phil, chief executive officer of Recode Therapeutics, Shehnaaz Suliman, said, “With the consistent contribution from organizations such as the CF foundation and our partnership with Praxis, we are forming our strong momentum to serve on the commitment to genetic medicines for individuals suffering from genetic diseases. A disease that hardly has few or no effective treatments as such.”
Recode has funded over $29 million to enhance its portfolio of genetic medicines, consisting of investigational therapies for cystic fibrosis (CF). This funding waters the industry’s financial roots as it plants its clinical and preclinical programs. The additional support from the CF Foundation, lastly invested around $15 million to help the development of clinical trials for RCT2100. Additionally, an additional $3 million to help the company’s recent phase 2 clinical trial of RCT2100.
The RCT2100 is engineered to deliver functional CFTR protein by serving an accurate copy of CFTR mRNA to lung cells, providing key benefits to individuals with CF, including those with disturbing and rare mutations. Overall, the foundation has confirmed to invest up to $33 million in Recode’s gene editing research and mRNA programs. For additional updates, visit www.CF-Clinical-Studies.com.
Alongside, recode has entered a research partnership with Praxis Precision Medicines Inc., a leading clinical-stage biopharmaceutical company, précising genetic insights into the development of therapies for central nervous system disorders defined by neuronal excitation-inhibition imbalance. Further, to address a tolerated lipid nanoparticle (LNP) foundation that improves the delivery of the antisense oligonucleotides to underexposed brain areas.
Recode leadership will be present at the European Respiratory Society (ERS) congress in Amsterdam, Netherlands, from 27 to 1st October 2025, and the North American cystic fibrosis conference (NACFC) in Seattle from 22nd October to 25th October 2025.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
